Esophageal Subepithelial Lesions
Conditions
Brief summary
This is a single-blinded randomized control trial trying to compare the effectiveness of diagnosis between two techniques employed in tissue sampling for subepithelial tumors (SETs) of the gastrointestinal tract. Over 2 years, patients having SET will be randomized to either get the EUS-guided core needle biopsy (EUS-CNB) or EUS-guided single-incision with needle knife (SINK) technique. This is of grave importance because the diagnosis of the myriad types of SETs is made histologically requiring a good sample.
Detailed description
Upper gastrointestinal (GI) subepithelial tumors (SETs) are tumors arising from subepithelial layers of esophageal, gastric or duodenal wall, mostly from the submucosa and muscular layer. The incidence of SETs on routine endoscopy is 0.36% The differential diagnosis of SETs include, though are not limited to: lipoma, leiomyoma, aberrant pancreas, varices, carcinoid, gastrointestinal stromal tumors (GISTs), and lymphomas . Therefore, a correct diagnosis of these tumors is important to guide subsequent management. These lesions are often not accurately diagnosed on cross-sectional imaging . Endoscopic ultrasound (EUS) aids in narrowing the differential diagnosis of the lesion as it is often able to establish the layer of origin . However, an accurate diagnosis and targeted therapy is not made solely on the morphological features but on histologic type and at times mitotic index. Thus the need for techniques to obtain histology is beneficial in guiding management. Since standard endoscopy with pinch biopsies of the overlying mucosa often fails to provide an adequate sample for analysis, multiple other modalities to sample the lesion have been utilized: EUS-guided fine needle aspiration (EUS-FNA), EUS-guided core needle biopsy (EUS-CNB), bite-on-bite forceps biopsies, EUS-guided single-incision with needle knife (SINK) and endoscopic resection. EUS-FNA is now considered to be the usual method of sampling; however, the diagnostic yield is low: 38% to 82% . Moreover, EUS-FNA often provides insufficient specimens which may not allow for immunohistochemistry that is often essential for diagnosis . Thus EUS-CNB has been assessed for the purpose of obtaining a core sample which allows for histological assessment. Published data reveals a diagnostic (though not histologic) yield using EUS-CNB of 75% In 2011, the SINK technique for sampling was presented with a reported diagnostic accuracy of 92.8% \[8\]. The technique utilizes a conventional needle-knife connected to an electrosurgical unit. A 6 to 12-mm mucosal incision is made over the lesion. Then conventional biopsy forceps are introduced to obtain 3-5 samples. Subsequently, the incision is closed with 2 to 3 endoclips. The purpose of this study is to prospectively compare the efficacy and safety of EUS-CNB with SINK in patients with upper GI SETs. The investigators hypothesis is that the SINK technique will be superior to the EUS-CNB in obtaining a histological specimen. The results of the study would provide data which may improve the diagnostic ability for SETs. This in turn will guide appropriate surveillance or management (surgical or endoscopic) for patients with these lesions.
Interventions
Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that, the procedure terminated.
Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients referred for EUS evaluation of upper GI SETs measuring an estimated 15mm or greater in maximal diameter. * Location of SET: esophagus, stomach, duodenum * Age \>18 years and older * Patient consent obtained
Exclusion criteria
* Endoscopically non bulging lesion * Upper GI SETs \<15 mm in size as measured during study EUS * Lesions not necessitating tissue acquisition: i.e. lipomas, varices * Cystic lesion * Patients \< 18 years of age * Uncorrectable Coagulopathy (INR \>1,5, platelets \<100,000) * Patients with stigmata of portal hypertension * Patients with post-surgical UGI anatomy (Roux-en-Y gastric bypass, esophagectomy etc) * Uncooperative patients * Pregnant women (women of childbearing age will undergo urine pregnancy testing, which is routine for all endoscopic procedures) * Refusal to consent form
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic Accuracy | 30 days | Diagnostic accuracy is defined as the percentage of true positive and true negative biopsy specimens combined divided by total number of specimens |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Histological Yield | 30 days | This will be assessed by the percentage of patients whose samples were adequate for histopathological evaluation |
| Technical Failure Rate | 1 day | Percentage of procedures in whom sampling technique failed to take biopsy specimens |
| Time of the Procedure | Tissue sampling procedure, up to 60 minutes | Time from the beginning of the incision or needle insertion, to completion of tissue acquisition by the techniques defined in the protocol. |
| Percent Sample Contribution to Immunohistochemistry Diagnosis | 30 days | Percentage of all samples from participants in whom biopsy specimen was adequate enough to contribute to immunohistochemistry diagnosis |
Countries
United States
Participant flow
Pre-assignment details
Patients were excluded from the study because a predominantly cystic lesion was found; the lack of an appreciable mass at Endoscopic Ultrasound scan (EUS).
Participants by arm
| Arm | Count |
|---|---|
| EUS-CNB Endoscopic ultrasound-core needle biopsy technique
22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC): A core-needle will be used to take a biopsy from the subepithelial lesion | 26 |
| EUS-SINK Endoscopic ultrasound- single incision needle knife technique
conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass): Needle knife sphincterotome will be used to take a biopsy of the subepithelial lesion | 30 |
| Total | 56 |
Baseline characteristics
| Characteristic | EUS-SINK | Total | EUS-CNB |
|---|---|---|---|
| Age, Continuous | 66.2 years STANDARD_DEVIATION 13.4 | 67.4 years STANDARD_DEVIATION 12.7 | 68.7 years STANDARD_DEVIATION 11.9 |
| Calcification No | 26 participants | 52 participants | 26 participants |
| Calcification Yes | 4 participants | 4 participants | 0 participants |
| Echogenicity Hyperechoic | 1 participants | 2 participants | 1 participants |
| Echogenicity Hypoechoic | 22 participants | 41 participants | 19 participants |
| Echogenicity Isoechoic | 7 participants | 12 participants | 5 participants |
| Echogenicity Mixed echogenicity | 0 participants | 1 participants | 1 participants |
| Greatest diameter of the lesion | 25 millimeters | 24.5 millimeters | 23.5 millimeters |
| Layer of origin Indeterminate | 4 participants | 6 participants | 2 participants |
| Layer of origin Muscularis propria | 17 participants | 34 participants | 17 participants |
| Layer of origin Submucosa | 9 participants | 16 participants | 7 participants |
| Location of the lesion Antrum | 7 participants | 11 participants | 4 participants |
| Location of the lesion Doudenum | 1 participants | 3 participants | 2 participants |
| Location of the lesion Esophagus | 1 participants | 2 participants | 1 participants |
| Location of the lesion Gastric body | 12 participants | 24 participants | 12 participants |
| Location of the lesion Gastric fundus | 9 participants | 16 participants | 7 participants |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Sex: Female, Male Female | 14 Participants | 25 Participants | 11 Participants |
| Sex: Female, Male Male | 16 Participants | 31 Participants | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 26 | 0 / 30 |
| other Total, other adverse events | 2 / 26 | 3 / 30 |
| serious Total, serious adverse events | 0 / 26 | 0 / 30 |
Outcome results
Diagnostic Accuracy
Diagnostic accuracy is defined as the percentage of true positive and true negative biopsy specimens combined divided by total number of specimens
Time frame: 30 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| EUS-CNB | Diagnostic Accuracy | 94.7 percentage of all samples |
| SINK | Diagnostic Accuracy | 95.5 percentage of all samples |
Histological Yield
This will be assessed by the percentage of patients whose samples were adequate for histopathological evaluation
Time frame: 30 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| EUS-CNB | Histological Yield | 76.9 percentage of participants |
| SINK | Histological Yield | 86.6 percentage of participants |
Percent Sample Contribution to Immunohistochemistry Diagnosis
Percentage of all samples from participants in whom biopsy specimen was adequate enough to contribute to immunohistochemistry diagnosis
Time frame: 30 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| EUS-CNB | Percent Sample Contribution to Immunohistochemistry Diagnosis | 94.7 percentage of all samples |
| SINK | Percent Sample Contribution to Immunohistochemistry Diagnosis | 86.4 percentage of all samples |
Technical Failure Rate
Percentage of procedures in whom sampling technique failed to take biopsy specimens
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| EUS-CNB | Technical Failure Rate | 3.3 percentage of procedures |
| SINK | Technical Failure Rate | 3.8 percentage of procedures |
Time of the Procedure
Time from the beginning of the incision or needle insertion, to completion of tissue acquisition by the techniques defined in the protocol.
Time frame: Tissue sampling procedure, up to 60 minutes
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| EUS-CNB | Time of the Procedure | 12 minutes |
| SINK | Time of the Procedure | 11 minutes |